1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
HUONS CO., LTD

HUONS CO., LTD

KKRX:243070
17,370.00
KRW
-120.00
(-0.69%)
2,562.48EPS
9.63P/E
295.37BMarket Cap
Nov 12Next Earn
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
14,129.09
19,864.76
27,508.06
30,571.97
34,127.7
36,882.73
41,617.21
46,601.15
49,837.98
53,126.9
52,920.92
Basic EPS, GAAP
1,282.2
2,445.76
3,786.63
3,200
4,664.55
2,596
1,897
4,261
2,487
3,651
2,633.49
Free Cash Flow per Basic Share
1,908.56
1,508.29
864.74
1,757.63
694.59
1,220.31
-903.2
622.85
-2,672.38
1,770.43
1,900.69
Dividend per Share
- -
- -
310.55
546.53
526.92
495.83
545.61
898.79
630.98
1,048.35
719.79
Book Value per Share
8,245.82
11,294.95
15,038.68
17,921.8
22,187.95
24,732.61
23,877.38
27,405.84
29,299.94
32,090.06
31,800.49
Tangible Book Value per Share
7,975.59
11,103.18
14,917.41
17,541.78
21,686.08
24,198.78
23,488.52
26,260.62
28,352.37
27,527.79
27,180.86
Basic Weighted Avg Shares
12
14
12
12
12
12
12
12
12
12
12
Sales/Revenue/Turnover
168,966
284,838
328,595
365,019
406,678
436,911
492,387
552,007
590,231
620,768
616,803
Operating Margin (%)
12.74
12.72
13.77
13.26
13.31
10.36
8.3
10.15
6.73
7.35
5.21
Depreciation Expense
4,185
5,255
6,424
9,837
11,830
12,845
16,731
18,232
20,930
26,975
29,963
Net Income, GAAP
15,334
35,069
45,233
38,207
55,584
30,752
22,444
50,473
29,454
42,661
30,694
Effective Tax Rate (%)
25.38
22.42
20.32
21.78
20.91
25.16
43.84
20.16
23.57
13.34
18.25
Profit Margin (%)
9.07
12.31
13.77
10.47
13.67
7.04
4.56
9.14
4.99
6.87
4.98
Working Capital
38,513
73,594
95,771
104,765
142,645
86,977
143,562
137,456
103,414
118,878
93,727
LT Debt
436
10,000
3,000
1,381
34,250
7,056
72,005
62,861
91,103
83,327
66,543
Total Equity
95,740
124,290
167,682
198,221
243,504
270,635
287,520
330,412
350,595
414,861
408,026
Return on Invested Capital (%)
- -
18.78
20.05
17.56
14.74
9.78
6.24
10.69
6.27
7.16
4.74
Return on Capital (%)
- -
25.01
26.73
18.93
19.63
9.61
6.52
12.43
6.58
8.64
5.68
Return on Common Equity (%)
- -
32.39
31.64
21.36
25.66
12.18
8.18
16.61
8.77
11.85
8.5

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
87,573
95,032
102,485
LT Borrowings
80,090
82,319
65,688
LT Finance Leases
1,032
1,007
855
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
12
12
12
Market Capitalization
346,640
319,258
295,372

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
285,723
289,636
273,897
Cash, Cash Equivalents & STI
74,222
66,176
64,568
Accounts Receivable, Net
105,015
114,499
95,952
Inventories
91,840
94,366
98,754
Total Current Liabilities
156,731
170,758
180,170
Payables & Accruals
- -
- -
- -
ST Debt
87,573
95,032
102,485
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
11.35%
18.33%
Free Cash Flow
- -
-192.53%
-165.36%
Net Income, GAAP
- -
11.28%
44.84%
Sales/Revenue/Turnover
- -
8.87%
5.17%
Total Cash Common Dividend
- -
20.5%
63.93%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
147,760
148,981
146,867
146,623
590,231
2025
145,836
156,030
153,717
165,185
620,768
2026
141,871
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
832
715
604
333.69
2,487
2025
1,046
993
680
930.98
3,651
2026
29.12
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
300.49
- -
630.98
2025
- -
- -
150
570
1,048.35
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Su-Young Song
Full Time Employees
1,087
Sector
Health technology
Industry
Pharmaceuticals: major
Address
#253C-902 Pangyo-ro Seongnam-si GY South Korea 13486
IPO Date
Jun 3, 2016
Website
huons.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Huons Co., Ltd. (243070.KQ) develops, manufactures, and markets pharmaceutical and biopharmaceutical products in South Korea and internationally. The company offers a diverse portfolio of generic and branded pharmaceuticals, including anti-infectives such as antibiotics and antivirals; cardiovascular drugs like antihypertensives and lipid regulators; central nervous system medications encompassing antidepressants and antipsychotics; gastrointestinal treatments including proton pump inhibitors; oncology therapeutics; and vaccines; alongside medical devices, plasma derivatives, and contract development and manufacturing organization (CDMO) services for biologics. Huons operates primarily in the healthcare sector, targeting hospitals, pharmacies, and wholesalers, with production facilities in Seongnam, South Korea, where it was founded in 1973 and maintains its headquarters. Recent developments include the launch of new biosimilar products, such as a denosumab biosimilar for osteoporosis treatment approved in 2024, and expansion into advanced biologics manufacturing through investments in cell and gene therapy platforms. In 2023, Huons formed a strategic partnership with a leading U.S. biotech firm for co-development of next-generation antibody therapeutics and completed a funding round exceeding KRW 200 billion to support R&D and global market entry into Southeast Asia and Europe. The company also acquired a subsidiary focused on rare disease treatments in late 2024, enhancing its pipeline in orphan drugs and specialty pharmaceuticals.